Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words 'ESTEY EH' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 71 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Estey, EH
      Growth factors in acute myeloid leukaemia

      BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
    2. Estey, EH
      Prognostic factors in acute myelogenous leukemia

      LEUKEMIA
    3. Bibawi, S; Abi-Said, D; Fayad, L; Anderlini, P; Ueno, NT; Mehra, R; Khouri, I; Giralt, S; Gajewski, J; Donato, M; Claxton, D; Braunschweig, I; van Besien, K; Andreeff, M; Andersson, BS; Estey, EH; Champlin, R; Przepiorka, D
      Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia

      AMERICAN JOURNAL OF HEMATOLOGY
    4. Beran, M; Shen, Y; Kantarjian, H; O'Brien, S; Koller, CA; Giles, FJ; Cortes, J; Thomas, DA; Faderl, S; Despa, S; Estey, EH
      High-dose chemotherapy in high-risk myelodysplastic syndrome - Covariate-adjusted comparison of five regimens

      CANCER
    5. Estey, EH
      Therapeutic options for acute myelogenous leukemia

      CANCER
    6. Giles, FJ; Kantarjian, HM; Kornblau, SM; Thomas, DA; Garcia-Manero, G; Waddelow, TA; David, CL; Phan, AT; Colburn, DE; Rashid, A; Estey, EH
      Mylotarg(TM) (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

      CANCER
    7. Estey, EH; Thall, PF; Cortes, JE; Giles, FJ; O'Brien, S; Pierce, SA; Wang, XM; Kantarjian, HM; Beran, M
      Comparison of idarubicin plus ara-C-, fludarabine plus ara-C-, and topotecan plus ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

      BLOOD
    8. Thall, PF; Estey, EH
      Graphical methods for evaluating covariate effects in the Cox model

      HANDBOOK OF STATISTICS IN CLINICAL ONCOLOGY
    9. Estey, EH
      Treatment of relapsed and refractory acute myelogenous leukemia

      LEUKEMIA
    10. Estey, EH; Pierce, S; Keating, MJ
      Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities

      HAEMATOLOGICA
    11. Estey, EH
      How I treat older patients with AML

      BLOOD
    12. Estey, EH; Shen, Y; Thall, PF
      Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB

      BLOOD
    13. Ibrahim, S; Estey, EH; Pierce, S; Glassman, A; Keating, M; O'Brien, S; Kantarjian, HM; Albitar, M
      11q23 Abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses

      AJCP. American journal of clinical pathology
    14. Estey, EH; Thall, PF; Reed, P; Kantarjian, H; Beran, M; Pierce, S; Keating, MJ
      Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy

      LEUKEMIA
    15. Seymour, JF; Juneja, SK; Campbell, LJ; Ellims, PH; Estey, EH; Prince, HM
      Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensifiedara-C therapy

      LEUKEMIA
    16. Andreeff, M; Jiang, S; Zhang, X; Konopleva, M; Estrov, Z; Snell, VE; Xie, Z; Okcu, MF; Sanchez-Williams, G; Dong, J; Estey, EH; Champlin, RC; Kornblau, SM; Reed, JC; Zhao, S
      Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid

      LEUKEMIA
    17. Thall, PF; Lee, JJ; Tseng, CH; Estey, EH
      Accrual strategies for phase I trials with delayed patient outcome

      STATISTICS IN MEDICINE
    18. Thall, PF; Estey, EH; Sung, HG
      A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials

      INVESTIGATIONAL NEW DRUGS
    19. Cortes, JE; Kantarjian, HM; O'Brien, S; Giles, F; Keating, MJ; Freireich, EJ; Estey, EH
      A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission

      CANCER
    20. Estrov, Z; Manna, SK; Harris, D; Van, Q; Estey, EH; Kantarjian, HM; Talpaz, M; Aggarwal, BB
      Phenylarsine oxide blocks interleukin-1 beta-induced activation of the nuclear transcription factor NF-kappa B, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells

      BLOOD
    21. Estey, EH; Giles, FJ; Kantarjian, H; O'Brien, S; Cortes, J; Freireich, EJ; Lopez-Berestein, G; Keating, M
      Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia

      BLOOD
    22. Estey, EH; Thall, PF; Pierce, S; Cortes, J; Beran, M; Kantarjian, H; Keating, MJ; Andreeff, M; Freireich, E
      Randomized phase II study of fludarabine plus cytosine arabinoside plus idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome

      BLOOD
    23. Konopleva, M; Mikhail, A; Estrov, Z; Zhao, SR; Harris, D; Sanchez-Williams, G; Kornblau, SM; Dong, J; Kliche, KO; Jiang, SW; Snodgrass, HR; Estey, EH; Andreeff, M
      Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: Proliferative and anti-apoptotic activities

      BLOOD
    24. Weinkauff, R; Estey, EH; Starostik, P; Hayes, K; Huh, YO; Hirsch-Ginsberg, C; Andreeff, M; Keating, M; Kantarjian, HM; Freireich, EJ; Albitar, M
      Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia

      AJCP. American journal of clinical pathology
    25. Aboul-Nasr, R; Estey, EH; Kantarjian, HM; Freireich, EJ; Andreeff, M; Johnson, BJ; Albitar, M
      Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens

      AJCP. American journal of clinical pathology
    26. FERRAJOLI A; TALPAZ M; KURZROCK R; HARRIS D; VAN Q; ESTEY EH; ESTROV Z
      THROMBOPOIETIN STIMULATES MYELODYSPLASTIC SYNDROME GRANULOCYTE-MACROPHAGE AND ERYTHROID PROGENITOR PROLIFERATION

      Leukemia & lymphoma
    27. ESTEY EH
      NEW AGENTS FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA - FOCUS ONTOPOTECAN AND RETINOIDS

      Leukemia
    28. ESTEY EH
      PROGNOSIS AND THERAPY OF SECONDARY MYELODYSPLASTIC SYNDROMES

      Haematologica
    29. ESTROV Z; THALL PF; TALPAZ M; ESTEY EH; KANTARJIAN HM; ANDREEFF M; HARRIS D; VAN Q; WALTERSCHEID M; KORNBLAU SM
      CASPASE-2 AND CASPASE-3 PROTEIN-LEVELS AS PREDICTORS OF SURVIVAL IN ACUTE MYELOGENOUS LEUKEMIA

      Blood
    30. MUNKER R; KANTARJIAN H; OBRIEN S; KEATING M; ANDREEFF M; ESTEY EH
      PHASE-I STUDY OF TAXOL IN REFRACTORY ACUTE MYELOGENOUS LEUKEMIAS USING A WEEKLY SCHEDULE

      Acta haematologica
    31. ESTEY EH
      TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA - REPLY

      Journal of clinical oncology
    32. PELEG S; QIU HY; REDDY S; HARRIS D; VAN Q; ESTEY EH; TALPAZ M; ESTROV Z
      1,25-DIHYDROXYVITAMIN D-3 AND ITS ANALOGS INHIBIT ACUTE MYELOGENOUS LEUKEMIA PROGENITOR PROLIFERATION BY SUPPRESSING INTERLEUKIN-1-BETA PRODUCTION

      The Journal of clinical investigation
    33. GHADDAR HM; PIERCE S; KANTARJIAN HM; FREIREICH EJ; KEATING MJ; ESTEY EH
      AMSACRINE AND CONTINUOUS-INFUSION HIGH-DOSE CYTOSINE-ARABINOSIDE AS INDUCTION THERAPY FOR PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA

      Leukemia & lymphoma
    34. ESCUDIER SM; KANTARJIAN HM; ESTEY EH
      THROMBOSIS IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITHAND WITHOUT ALL-TRANS-RETINOIC ACID

      Leukemia & lymphoma
    35. ANDERLINI P; GHADDAR HM; SMITH TL; PIERCE S; KANTARJIAN HM; OBRIEN S; KEATING MJ; FREIREICH EJ; ESTEY EH
      FACTORS PREDICTING COMPLETE REMISSION AND SUBSEQUENT DISEASE-FREE SURVIVAL AFTER A 2ND COURSE OF INDUCTION THERAPY IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA RESISTANT TO THE FIRST

      Leukemia
    36. ANDERLINI P; LUNA M; KANTARJIAN HM; OBRIEN S; PIERCE S; KEATING MJ; ESTEY EH
      CAUSES OF INITIAL REMISSION INDUCTION FAILURE IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA AND MYELODYSPLASTIC SYNDROMES

      Leukemia
    37. KANTARJIAN HM; BERAN M; OBRIEN S; ROBERTSON L; SIDDIK Z; YOSHIDA M; YANG LY; RIOS MB; KEATING MJ; MEYER M; KOWAL C; ESTEY EH
      EVALUATION OF CL-973, A PLATINUM ANALOG, IN REFRACTORY OR RELAPSED ACUTE-LEUKEMIA

      Leukemia
    38. WILHELM M; KANTARJIAN HM; OBRIEN S; PIERCE S; KEATING MJ; FREIREICH EJ; ESTEY EH
      PNEUMONIA DURING REMISSION INDUCTION CHEMOTHERAPY IN PATIENTS WITH AML OR MDS

      Leukemia
    39. GALE RP; HOROWITZ MM; REES JKH; GRAY RG; OKEN MM; ESTEY EH; KIM KM; ZHANG MJ; ASH RC; ATKINSON K; CHAMPLIN RE; DICKE KA; GAJEWSKI JL; GOLDMAN JM; HELBIG W; HENSLEEDOWNEY PJ; HINTERBERGER W; JACOBSEN N; KEATING A; KLEIN JP; MARMONT AM; PRENTICE HG; REIFFERS J; RIMM AA; ROWLINGS PA; SOBOCINSKI KA; SPECK B; WINGARD JR; BORTIN MM
      CHEMOTHERAPY VERSUS TRANSPLANTS FOR ACUTE MYELOGENOUS LEUKEMIA IN 2NDREMISSION

      Leukemia
    40. POLLICARDO N; OBRIEN S; ESTEY EH; ALBITAR M; PIERCE S; KEATING M; KANTARJIAN HM
      SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA - CHARACTERISTICS AND PROGNOSIS OF 14 PATIENTS FROM A SINGLE INSTITUTION

      Leukemia
    41. KANTARJIAN HM; ESTEY EH; KEATING MA
      NEW CHEMOTHERAPEUTIC-AGENTS IN ACUTE MYELOID-LEUKEMIA

      Leukemia
    42. THALL PF; SIMON RM; ESTEY EH
      NEW STATISTICAL STRATEGY FOR MONITORING SAFETY AND EFFICACY IN SINGLE-ARM CLINICAL-TRIALS

      Journal of clinical oncology
    43. WILHELM M; KANTARJIAN HM; OBRIEN S; PIERCE S; KEATING MJ; FREIREICH EJ; ESTEY EH
      PNEUMONIA DURING REMISSION INDUCTION CHEMOTHERAPY IN PATIENTS WITH AML OR MDS

      Blood
    44. ESTEY EH; KANTARJIAN HM; OBRIEN S; KORNBLAU S; ANDREEFF M; BERAN M; PIERCE S; KEATING M
      HIGH REMISSION RATE, SHORT REMISSION DURATION IN PATIENTS WITH REFRACTORY-ANEMIA WITH EXCESS BLASTS (RAEB) IN TRANSFORMATION (RAEB-T) GIVENACUTE MYELOGENOUS LEUKEMIA (AML)-TYPE CHEMOTHERAPY IN COMBINATION WITH GRANULOCYTE-CSF (G-CSF)

      Cytokines and molecular therapy
    45. SEYMOUR JF; ESTEY EH
      THE CONTRIBUTION OF AUER RODS TO THE CLASSIFICATION AND PROGNOSIS OF MYELODYSPLASTIC SYNDROMES

      Leukemia & lymphoma
    46. GHADDAR HM; PIERCE S; REED P; ESTEY EH
      PROGNOSTIC VALUE OF RESIDUAL NORMAL METAPHASES IN ACUTE MYELOGENOUS LEUKEMIA PATIENTS PRESENTING WITH ABNORMAL KARYOTYPE

      Leukemia
    47. SEYMOUR JF; ESTEY EH; KEATING MJ; KURZROCK R
      RESPONSE TO INTERFERON-ALPHA IN PATIENTS WITH HAIRY-CELL LEUKEMIA RELAPSING AFTER TREATMENT WITH 2-CHLORODEOXYADENOSINE

      Leukemia
    48. ANDERLINI P; BENJAMIN RS; WONG FC; KANTARJIAN HM; ANDREEFF M; KORNBLAU SM; OBRIEN S; MACKAY B; EWER MS; PIERCE SA; ESTEY EH
      IDARUBICIN CARDIOTOXICITY - A RETROSPECTIVE STUDY IN ACUTE MYELOID-LEUKEMIA AND MYELODYSPLASIA

      Journal of clinical oncology
    49. ESTROV Z; TALPAZ M; ESTEY EH; STRASSMANN G
      ROLE OF SURAMIN AS AN IL-1 INHIBITOR IN SUPPRESSION OF ACUTE MYELOGENOUS LEUKEMIA PROGENITOR PROLIFERATION

      Experimental hematology
    50. THALL PF; SIMON RM; ESTEY EH
      BAYESIAN SEQUENTIAL MONITORING DESIGNS FOR SINGLE-ARM CLINICAL-TRIALSWITH MULTIPLE OUTCOMES

      Statistics in medicine
    51. ESTEY EH
      TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA AND MYELODYSPLASTIC SYNDROME

      Seminars in hematology
    52. ESTEY EH; KEATING MJ
      POSTREMISSION CHEMOTHERAPY FOR ACUTE MYELOID-LEUKEMIA

      The New England journal of medicine
    53. ESTROV Z; BLACK RA; SLEATH PR; HARRIS D; VAN Q; LAPUSHIN R; ESTEY EH; TALPAZ M
      EFFECT OF INTERLEUKIN-1-BETA CONVERTING-ENZYME-INHIBITOR ON ACUTE MYELOGENOUS LEUKEMIA PROGENITOR PROLIFERATION

      Blood
    54. MARLTON P; CLAXTON DF; LIU P; ESTEY EH; BERAN M; LEBEAU M; TESTA JR; COLLINS FS; ROWLEY JD; SICILIANO MJ
      MOLECULAR CHARACTERIZATION OF 16P DELETIONS ASSOCIATED WITH INVERSION-16 DEFINES THE CRITICAL FUSION FOR LEUKEMOGENESIS

      Blood
    55. ZHAO L; CHANG KS; ESTEY EH; HAYES K; DEISSEROTH AB; LIANG JC
      DETECTION OF RESIDUAL LEUKEMIC-CELLS IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA BY THE FLUORESCENCE IN-SITU HYBRIDIZATION METHOD - POTENTIAL FOR PREDICTING RELAPSE

      Blood
    56. GHADDAR HM; PLUNKETT W; KANTARJIAN HM; PIERCE S; FREIREICH EJ; KEATING MJ; ESTEY EH
      LONG-TERM RESULTS FOLLOWING TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA WITH CONTINUOUS-INFUSION HIGH-DOSE CYTOSINE-ARABINOSIDE

      Leukemia
    57. SEYMOUR JF; PIERCE SA; KANTARJIAN HM; KEATING MJ; ESTEY EH
      INVESTIGATION OF KARYOTYPIC, MORPHOLOGIC AND CLINICAL-FEATURES IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA BLAST CELLS EXPRESSING THE NEURAL CELL-ADHESION MOLECULE (CD56)

      Leukemia
    58. GHADDAR HM; STASS SA; PIERCE S; ESTEY EH
      CYTOGENETIC EVOLUTION FOLLOWING THE TRANSFORMATION OF MYELODYSPLASTIC-SYNDROME TO ACUTE MYELOGENOUS LEUKEMIA - IMPLICATIONS ON THE OVERLAP BETWEEN THE 2 DISEASES

      Leukemia
    59. MARUYAMA F; STASS SA; ESTEY EH; CORK A; HIRANO M; INO T; FREIREICH EJ; YANG PR; CHANG KS
      DETECTION OF AML1 ETO FUSION TRANSCRIPT AS A TOOL OF DIAGNOSING T(821) POSITIVE ACUTE MYELOGENOUS LEUKEMIA/

      Leukemia
    60. ESTEY EH
      REGROWTH RESISTANCE

      Leukemia research
    61. KANTARJIAN HM; OBRIEN S; SMITH T; ESTEY EH; BERAN M; PRETI A; PIERCE S; KEATING MJ
      ACUTE LYMPHOCYTIC-LEUKEMIA IN THE ELDERLY - CHARACTERISTICS AND OUTCOME WITH THE VINCRISTINE-ADRIAMYCIN-DEXAMETHASONE (VAD) REGIMEN

      British Journal of Haematology
    62. ESTROV Z; BLACK RA; KURZROCK R; WETZLER M; SLEATH PR; ESTEY EH; HARRIS D; VAN Q; TALPAZ M
      IL-1-BETA CONVERTING-ENZYME (ICE) INHIBITOR SUPPRESSES AML BLAST PROLIFERATION

      Blood
    63. ESTEY EH
      USE OF COLONY-STIMULATING FACTORS IN THE TREATMENT OF ACUTE MYELOID-LEUKEMIA

      Blood
    64. SEYMOUR JF; KURZROCK R; FREIREICH EJ; ESTEY EH
      2-CHLORODEOXYADENOSINE INDUCES DURABLE REMISSIONS AND PROLONGED SUPPRESSION OF CD4(-CELL LEUKEMIA() LYMPHOCYTE COUNTS IN PATIENTS WITH HAIRY)

      Blood
    65. THALL PF; ESTEY EH
      A BAYESIAN STRATEGY FOR SCREENING CANCER TREATMENTS PRIOR TO PHASE-IICLINICAL-EVALUATION

      Statistics in medicine
    66. ESTEY EH; KANTARJIAN H; KEATING M
      IDARUBICIN PLUS CONTINUOUS-INFUSION HIGH-DOSE CYTARABINE AS TREATMENTFOR PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA OR MYELODYSPLASTIC SYNDROME

      Seminars in oncology
    67. JAIYESIMI IA; KANTARJIAN HM; ESTEY EH
      ADVANCES IN THERAPY FOR HAIRY-CELL LEUKEMIA - A REVIEW

      Cancer
    68. SEYMOUR JF; ESTEY EH
      THE PROGNOSTIC-SIGNIFICANCE OF AUER RODS IN MYELODYSPLASIA

      British Journal of Haematology
    69. SEYMOUR JF; PIERCE SA; KANTARJIAN H; KEATING MJ; ESTEY EH
      NEURAL CELL-ADHESION MOLECULE (CD56) EXPRESSION IS ASSOCIATED WITH FAB SUBTYPE, CYTOGENETICS AND SKIN INFILTRATION IN ACUTE MYELOID-LEUKEMIA (AML)

      Blood
    70. SEYMOUR JF; KURZROCK R; FREIREICH EJ; ESTEY EH
      PROLONGED CD4-CHLORODEOXYADENOSINE (2-CDA) IN PATIENTS (PTS) WITH HAIRY-CELL LEUKEMIA (HCL)( LYMPHOCYTOPENIA IS THE COST OF DURABLE RESPONSES TO 2)

      Blood
    71. READING CL; ESTEY EH; HUH YO; CLAXTON DF; SANCHEZ G; TERSTAPPEN LWMM; OBRIEN MC; BARON S; DEISSEROTH AB
      EXPRESSION OF UNUSUAL IMMUNOPHENOTYPE COMBINATIONS IN ACUTE MYELOGENOUS LEUKEMIA

      Blood


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/08/20 alle ore 02:15:34